SecBot SecBot
8-K ·Filed Apr 20, 2026

CABA

Cabaletta Bio, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001759138-26-000016
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor upcoming clinical data readouts in 1H26 for SLE and SSc, and watch for updates on automated manufacturing progress and regulatory pathway discussions with FDA.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.31
T+0 close · Apr 20, 2026 · via day close
Latest settled
−16.19%
T+60 · $2.77
Vs SPY
−22.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $3.31entry
  2. T+1 · 7mo ago −5.29%α −4.64% · $3.13
  3. T+5 · 7mo ago −11.95%α −12.86% · $2.91
  4. T+20 · 6mo ago −0.45%α −4.66% · $3.29
  5. T+60 · 4mo ago −16.19%α −22.97% · $2.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio updated its corporate presentation with clinical data showing positive safety and efficacy results from its autoimmune-focused CAR-T therapy rese-cel across multiple trials, including myositis, lupus, and myasthenia gravis, while advancing innovations in preconditioning elimination and automated manufacturing.

Key Facts

  • Posted updated corporate presentation with clinical data from RESET trials
  • Rese-cel demonstrated favorable safety profile with 95% of patients experiencing no or Grade 1 CRS
  • Positive efficacy data in multiple autoimmune conditions including myositis, SLE, and myasthenia gravis
  • Advancing innovations in preconditioning elimination and automated manufacturing
  • Pivotal myositis study enrolling with planned 2027 BLA submission

Financial Impact

No specific financial figures disclosed in the filing

revenueepspipeline_valuemarket_cap

Risk Factors

  • Clinical trial delays
  • Regulatory approval risks
  • Manufacturing scalability challenges

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759138-26-000016
Document: caba-20260420.htm0001759138-26-000016
Document: 0001759138-26-000016-index-headers.html0001759138-26-000016
Document: 0001759138-26-000016-index.html0001759138-26-000016
Document: 0001759138-26-000016.txt0001759138-26-000016

Track record

29 reports on CABA

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026